Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder

B. NOSYK ; J. E. MIN ; F. HOMAYRA ; M. KURZ ; B. C. GUERRA-ALEJOS ; R. YAN ; M. PISKE ; S. R. SEAMAN ; P. BACH ; S. GREENLAND ; M. E. KARIM ; U. SIEBERT ; J. BRUNEAU ; P. GUSTAFSON ; K. KAMPMAN ; P. T. KORTHUIS ; T. LOUGHIN ; L. C. MCCANDLESS ; R. W. PLATT ; K. T. SCHNEPEL ; M. E. SOCIAS | 2024
Dans Journal of the American Medical Association (Vol.332, n°21, December 3, 2024) Article : Périodique

Key points: Question: Is buprenorphine/naloxone associated with lower risk of treatment discontinuation and mortality compared with methadone? Findings: In this population-based retrospective cohort study that included 30?891 individuals initi[...]

Plus d'info

Ajouter à la sélection

Lien externe

Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

L. A. PEARCE ; J. E. MIN ; M. PISKE ; H. ZHOU ; F. HOMAYRA ; A. SLAUNWHITE ; M. IRVINE ; G. MCGOWAN ; B. NOSYK | 2020
Dans British Medical Journal (Vol.368, n°8240, 4 April 2020) Article : Périodique

Objective: To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit [...]

Plus d'info

Ajouter à la sélection

Lien externe